* Organogenesis Holdings Inc ORGO.OQ reported quarterly
adjusted
earnings of 9 cents per share for the quarter , higher than
the same quarter last year, when the company reported EPS of 2
cents. The mean expectation of four analysts for the quarter
was for a loss of one cent per share. Wall Street expected
results to range from -2 cents tozero cents per share.
* Revenue rose 6.1% to $115.18 million from a year ago;
analysts
expected $108.83 million.
* Organogenesis Holdings Inc's reported EPS for the quarter
was 9
cents.
* The company reported quarterly net income of $12.33
million.
* Organogenesis Holdings Inc shares had risen by 20.6% this
quarter and lost 15.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Organogenesis
Holdings Inc is 4.40
This summary was machine generated from LSEG data November 13 at
02:27 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.01 0.09 Beat
Jun. 30 2024 0.00 0.04 Beat
Mar. 31 2024 -0.03 -0.02 Beat
Dec. 31 2023 0.01 0.00 Missed